Oncology Booming But Cost Outlook Grim, IMS Says
This article was originally published in PharmAsia News
Executive Summary
The cost of oncology therapeutics and supportive care drugs grew 11.5% to $107bn in 2015 at constant exchange rates and is expected to reach $150bn globally in 2020, according to a new report.
You may also be interested in...
Multi-Indication Pricing: Big Hurdles And Actionable Options
Pricing drugs differently by indication presents an opportunity to better align the cost of medicines to value in certain cases, but the regulatory, policy and administrative challenges are daunting. Experts debated the challenges and opportunities during the ISPOR annual meeting.
Industry’s Rebate Arms Race: Securing Market Access At A Cost
Rebates have become industry’s go-to for securing market access for drugs in competitive therapeutic areas in the US. But as payers push back, competitive rebating is intensifying and eating into the bottom line.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.